There are no current vacancies.
We are always interested in hearing from experienced scientists and managers who would like to work with us. Therefore, please feel free to send us your CV using the form below, should you wish to be considered for other vacancies that may arise in the future.
Send Us Your CV
Please use this form to send us your details and up to date CV.
Apitope to attend the JP Morgan 38th Annual Healthcare Conference 13-16 January 2020 in San Francisco, CA, USA
Apitope's Chief Executive Officer Hayley French and Chief Research Officer Lotta Jansson will be attending JP Morgan 38th Annual Healthcare Conference 13-16 January 2020 in San Francisco. Please contact Hayley.French@apitope.com or Lotta.Jansson@apitope.com for further information
Apitope’s Antigen specific immunotherapy for Graves’ disease features in the October 2019 edition of the British Thyroid Foundation Newsletter
Apitope’s Antigen specific immunotherapy for Graves’ disease features in the October 2019 edition of the British Thyroid Foundation Newsletter (BTF) and the article is also available on the BTF website by following this link: https://www.btf-thyroid.org/research-news-graves-disease
Apitope announces that the first in human clinical trial for the treatment of Graves’ disease has been published as a ‘Success Story’ by the European Commission
HASSELT, Belgium, and CHEPSTOW, UK, 13 September 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that the first in human clinical trial for the treatment of Graves’ disease funded by the European Union (DAVIAD) has been published as a “Success Story” on the European Union website. The article entitled ‘ New treatment on the horizon for Graves' disease’ can be viewed in the following link: https://ec.europa.eu/research/infocentre/article_en.cfm?artid=50625
Apitope Announces Publication of Data in International Peer-Reviewed Journal Thyroid on Graves’ disease Therapy
HASSELT, Belgium, and CHEPSTOW, UK, 20 June 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its clinical Graves’ disease data in Thyroid, one of the leading peer-reviewed thyroid disease related medical journals. The publication entitled: Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study , reports the results from a first in human clinical study to assess the safety, tolerability and efficacy of Apitope’s antigen-specific immunotherapy, ATX-GD-59, in patients with Graves’ disease. The open-label trial reported in the paper was conducted in patients with mild to moderate Graves’ disease. These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid function in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves' hyperthyroidism. Hayley French, CEO of Apitope, said: “We are delighted that these data have been published in Thyroid, a peer-reviewed journal for thyroid related diseases. For people suffering from Graves’, the project’s progress has finally created hope that the underlying disease can be treated and, for the first time in over 70 years, an innovative disease modifying treatment could be on the horizon”. https://www.liebertpub.com/doi/full/10.1089/thy.2019.0036